Group 1 - As of August 4, 2025, Zhongheng Group's stock price is 2.74 yuan, down 0.02 yuan or 0.72% from the previous trading day [1] - The trading volume for the day was 616,400 hands, with a total transaction amount of 166.7 million yuan [1] - Zhongheng Group primarily engages in pharmaceutical manufacturing, with core products including thrombolytic agents for cardiovascular diseases [1] Group 2 - The company has a wholly-owned subsidiary, Zhongheng Innovation, which acquired a patent for a drug treating chronic heart failure for 55 million yuan [1] - This drug is a novel compound discovered by the Navy Medical University, significantly enhancing myocardial energy metabolism, and currently, there are no similar drugs on the market globally [1] - The company operates in various sectors, including pharmaceutical manufacturing, research and development, and health food, making it a key player in the Guangxi region [1]

Core Viewpoint - Zhongheng Group (600252.SH) is acquiring a patented technology for treating chronic heart failure from the Navy Medical University of the People's Liberation Army, aligning with its strategic development goals [1] Summary by Relevant Sections Acquisition Details - Zhongheng Innovation, a wholly-owned subsidiary of Zhongheng Group, plans to acquire the patent for a drug technology aimed at treating chronic heart failure [1] - The project has a base transfer price of RMB 55 million, with a deposit of RMB 500,000 required [1] - The transfer process includes an initial payment of at least RMB 5 million, due within 10 working days after the contract takes effect, followed by milestone payments upon the occurrence of specified events [1] Timeline and Confirmation - The transfer listing will end on June 18, 2025, with the confirmation of Zhongheng Innovation as the acquirer occurring on June 20, 2025 [1] - A formal contract for the technology transfer was signed between Zhongheng Innovation and the China Runtong Research Institute on August 1, 2025 [1]